News Roche pays $1.7 billion for cancer specialist Ignyta Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta.
News After surging on lung cancer data, Ignyta looks to raise $16... San Diego based biotech firm Ignyta is capping off a week of success with a public stock offering t
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.